Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 206.02 Thousand SEK | -64.98% |
| 2022 | 588.34 Thousand SEK | -46.42% |
| 2021 | 1.09 Million SEK | -39.19% |
| 2020 | 1.8 Million SEK | -12.38% |
| 2019 | 2.06 Million SEK | -16.53% |
| 2018 | 2.46 Million SEK | -77.03% |
| 2017 | 10.74 Million SEK | 498.45% |
| 2016 | 1.79 Million SEK | 124.47% |
| 2015 | 800 Thousand SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 205 Thousand SEK | -0.5% |
| 2024 Q2 | 205 Thousand SEK | 0.0% |
| 2023 Q3 | 206.02 Thousand SEK | 0.01% |
| 2023 Q4 | 206.02 Thousand SEK | 0.0% |
| 2023 Q1 | 206 Thousand SEK | -64.99% |
| 2023 Q2 | 206 Thousand SEK | 0.0% |
| 2023 FY | 206.02 Thousand SEK | -64.98% |
| 2022 Q4 | 588.34 Thousand SEK | 0.0% |
| 2022 Q3 | 588.34 Thousand SEK | -30.21% |
| 2022 Q2 | 843 Thousand SEK | 0.0% |
| 2022 Q1 | 843 Thousand SEK | -23.23% |
| 2022 FY | 588.34 Thousand SEK | -46.42% |
| 2021 Q1 | 1.35 Million SEK | -25.07% |
| 2021 Q3 | 1.09 Million SEK | -18.85% |
| 2021 FY | 1.09 Million SEK | -39.19% |
| 2021 Q4 | 1.09 Million SEK | 0.01% |
| 2021 Q2 | 1.35 Million SEK | 0.0% |
| 2020 Q4 | 1.8 Million SEK | -0.02% |
| 2020 Q2 | 1.97 Million SEK | -0.02% |
| 2020 Q1 | 1.97 Million SEK | -4.12% |
| 2020 FY | 1.8 Million SEK | -12.38% |
| 2020 Q3 | 1.8 Million SEK | -8.59% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | 2.06 Million SEK | -16.53% |
| 2019 Q4 | 2.06 Million SEK | -0.01% |
| 2019 Q2 | 2.31 Million SEK | 0.0% |
| 2019 Q3 | 2.06 Million SEK | -11.03% |
| 2018 FY | 2.46 Million SEK | -77.03% |
| 2017 FY | 10.74 Million SEK | 498.45% |
| 2016 FY | 1.79 Million SEK | 124.47% |
| 2015 FY | 800 Thousand SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.987% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.987% |
| Arcoma AB | 3.87 Million SEK | 94.681% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 99.912% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.989% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 99.876% |
| CellaVision AB (publ) | 64.7 Million SEK | 99.682% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | 54.62% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | 88.554% |
| Duearity AB (publ) | 10.58 Million SEK | 98.053% |
| Dignitana AB (publ) | 19.1 Million SEK | 98.922% |
| Episurf Medical AB (publ) | 5.2 Million SEK | 96.038% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.997% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 97.503% |
| Iconovo AB (publ) | 7.72 Million SEK | 97.333% |
| Integrum AB (publ) | 6.42 Million SEK | 96.793% |
| Mentice AB (publ) | 9.55 Million SEK | 97.844% |
| OssDsign AB (publ) | 3.15 Million SEK | 93.46% |
| Paxman AB (publ) | 13.57 Million SEK | 98.482% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 99.006% |
| SciBase Holding AB (publ) | 6.79 Million SEK | 96.969% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 99.352% |
| Sedana Medical AB (publ) | 4.3 Million SEK | 95.215% |
| Senzime AB (publ) | 11.46 Million SEK | 98.203% |
| SpectraCure AB (publ) | 6.71 Million SEK | 96.933% |
| Stille AB | 62.94 Million SEK | 99.673% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.99% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 99.345% |